Michele Fox
Concepts (436)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 31 | 2023 | 573 | 2.290 |
Why?
| Hematopoietic Stem Cells | 21 | 2018 | 215 | 2.050 |
Why?
| Multiple Myeloma | 44 | 2024 | 3035 | 1.960 |
Why?
| Bone Marrow Transplantation | 27 | 2016 | 149 | 1.930 |
Why?
| Hematopoietic Stem Cell Mobilization | 13 | 2018 | 61 | 1.550 |
Why?
| Antigens, CD34 | 20 | 2018 | 80 | 1.050 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 1056 | 0.870 |
Why?
| Blood Platelets | 5 | 2017 | 269 | 0.870 |
Why?
| Cell Separation | 8 | 2013 | 107 | 0.870 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 3 | 2018 | 17 | 0.770 |
Why?
| Blood Transfusion | 4 | 2017 | 138 | 0.690 |
Why?
| Melphalan | 8 | 2016 | 180 | 0.670 |
Why?
| Transplantation, Autologous | 21 | 2013 | 476 | 0.650 |
Why?
| Leukapheresis | 5 | 2018 | 16 | 0.640 |
Why?
| Fetal Blood | 4 | 2023 | 67 | 0.630 |
Why?
| Myelodysplastic Syndromes | 3 | 2013 | 79 | 0.590 |
Why?
| Graft vs Host Disease | 15 | 2003 | 83 | 0.550 |
Why?
| Leukocytes, Mononuclear | 5 | 2018 | 133 | 0.540 |
Why?
| Plasma Exchange | 3 | 2015 | 33 | 0.520 |
Why?
| Humans | 90 | 2024 | 54246 | 0.500 |
Why?
| Adult | 48 | 2019 | 14182 | 0.480 |
Why?
| Middle Aged | 42 | 2018 | 13070 | 0.450 |
Why?
| Flow Cytometry | 6 | 2016 | 546 | 0.440 |
Why?
| Granulocyte Colony-Stimulating Factor | 7 | 2012 | 69 | 0.430 |
Why?
| Killer Cells, Natural | 3 | 2015 | 107 | 0.420 |
Why?
| Pregnant Women | 1 | 2023 | 80 | 0.420 |
Why?
| Aged | 32 | 2017 | 10041 | 0.420 |
Why?
| Blood Component Removal | 4 | 2018 | 18 | 0.420 |
Why?
| Thalidomide | 6 | 2016 | 397 | 0.410 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 134 | 0.390 |
Why?
| Transplantation Conditioning | 8 | 2006 | 86 | 0.390 |
Why?
| Chromosome Aberrations | 5 | 2016 | 316 | 0.380 |
Why?
| Female | 49 | 2023 | 28418 | 0.380 |
Why?
| Cell Proliferation | 5 | 2018 | 1096 | 0.370 |
Why?
| Transplantation, Homologous | 13 | 2016 | 155 | 0.370 |
Why?
| Platelet Count | 4 | 2017 | 77 | 0.360 |
Why?
| Male | 46 | 2019 | 27312 | 0.350 |
Why?
| Antigens, CD | 10 | 2003 | 242 | 0.350 |
Why?
| Blood Specimen Collection | 1 | 2019 | 39 | 0.340 |
Why?
| Blood Volume | 1 | 2019 | 69 | 0.340 |
Why?
| Antibodies | 2 | 2016 | 178 | 0.330 |
Why?
| Education, Distance | 1 | 2019 | 39 | 0.330 |
Why?
| Cryopreservation | 3 | 2010 | 31 | 0.330 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 31 | 0.320 |
Why?
| Erythrocyte Transfusion | 3 | 2015 | 74 | 0.320 |
Why?
| Obstetrics | 1 | 2019 | 89 | 0.310 |
Why?
| Lymphoma | 3 | 2018 | 72 | 0.310 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2017 | 44 | 0.310 |
Why?
| Leukemia | 3 | 2013 | 69 | 0.310 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 6 | 0.310 |
Why?
| Blood Coagulation | 1 | 2017 | 69 | 0.300 |
Why?
| Leukocytes | 3 | 2011 | 85 | 0.300 |
Why?
| Graft Survival | 7 | 2011 | 165 | 0.290 |
Why?
| Bone Marrow Cells | 5 | 2004 | 233 | 0.290 |
Why?
| Follow-Up Studies | 11 | 2024 | 2387 | 0.280 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 142 | 0.280 |
Why?
| Aspirin | 1 | 2017 | 127 | 0.280 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2000 | 48 | 0.280 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 180 | 0.270 |
Why?
| Hemoglobins, Abnormal | 1 | 2015 | 4 | 0.260 |
Why?
| Heparin | 1 | 2015 | 97 | 0.260 |
Why?
| Thrombocytopenia | 1 | 2015 | 99 | 0.250 |
Why?
| Stem Cell Transplantation | 2 | 2013 | 196 | 0.250 |
Why?
| Factor VIII | 1 | 2014 | 28 | 0.250 |
Why?
| ADAM Proteins | 1 | 2014 | 24 | 0.250 |
Why?
| Methotrexate | 2 | 2001 | 73 | 0.250 |
Why?
| Anemia, Sickle Cell | 1 | 2015 | 94 | 0.240 |
Why?
| Retroviridae | 4 | 1997 | 10 | 0.230 |
Why?
| Dendritic Cells | 3 | 2010 | 142 | 0.230 |
Why?
| Combined Modality Therapy | 12 | 2014 | 692 | 0.230 |
Why?
| Neoplasm Recurrence, Local | 3 | 2015 | 644 | 0.230 |
Why?
| Cancer Vaccines | 3 | 2010 | 103 | 0.230 |
Why?
| Internship and Residency | 1 | 2019 | 501 | 0.220 |
Why?
| Cell Count | 7 | 2011 | 181 | 0.220 |
Why?
| Retrospective Studies | 11 | 2018 | 6432 | 0.220 |
Why?
| Prognosis | 8 | 2018 | 2118 | 0.220 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 40 | 0.220 |
Why?
| Cytomegalovirus Infections | 3 | 2001 | 46 | 0.220 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.220 |
Why?
| Cell Survival | 7 | 2011 | 657 | 0.220 |
Why?
| Graft vs Tumor Effect | 2 | 2006 | 3 | 0.210 |
Why?
| Bone Marrow | 8 | 1997 | 411 | 0.210 |
Why?
| Cytotoxicity Tests, Immunologic | 3 | 2016 | 31 | 0.210 |
Why?
| Leukemia, Myeloid | 2 | 2000 | 54 | 0.210 |
Why?
| Adenoviridae Infections | 1 | 2001 | 5 | 0.210 |
Why?
| Aldehyde Dehydrogenase | 1 | 2011 | 27 | 0.210 |
Why?
| Gene Transfer Techniques | 3 | 1997 | 41 | 0.210 |
Why?
| Treatment Outcome | 19 | 2013 | 5604 | 0.200 |
Why?
| Tamoxifen | 1 | 2001 | 60 | 0.200 |
Why?
| Boronic Acids | 2 | 2013 | 197 | 0.190 |
Why?
| Pyrazines | 2 | 2013 | 203 | 0.190 |
Why?
| Plateletpheresis | 1 | 2010 | 8 | 0.190 |
Why?
| Blood Preservation | 1 | 2010 | 29 | 0.190 |
Why?
| Myeloablative Agonists | 3 | 2007 | 33 | 0.190 |
Why?
| Blood Proteins | 1 | 2010 | 100 | 0.190 |
Why?
| Lymphoma, B-Cell | 1 | 2000 | 62 | 0.190 |
Why?
| Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 57 | 0.180 |
Why?
| Immunosuppressive Agents | 4 | 2014 | 248 | 0.180 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.180 |
Why?
| Fever | 1 | 2001 | 129 | 0.180 |
Why?
| Genetic Vectors | 4 | 1997 | 139 | 0.180 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2007 | 113 | 0.170 |
Why?
| Blood Cells | 4 | 1994 | 58 | 0.170 |
Why?
| Incidence | 7 | 2017 | 1082 | 0.170 |
Why?
| Disease-Free Survival | 7 | 2016 | 485 | 0.170 |
Why?
| Dexamethasone | 5 | 2024 | 435 | 0.170 |
Why?
| Receptors, KIR | 1 | 2008 | 15 | 0.170 |
Why?
| HIV Infections | 1 | 2013 | 394 | 0.160 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 866 | 0.160 |
Why?
| Cell Movement | 2 | 2006 | 271 | 0.150 |
Why?
| Immunoglobulins, Intravenous | 3 | 1992 | 55 | 0.150 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 25 | 0.150 |
Why?
| Cyclophosphamide | 7 | 2006 | 172 | 0.150 |
Why?
| Lymphocyte Transfusion | 3 | 2003 | 12 | 0.150 |
Why?
| Recurrence | 5 | 2008 | 690 | 0.140 |
Why?
| Risk Factors | 7 | 2015 | 3930 | 0.140 |
Why?
| Transformation, Genetic | 1 | 1995 | 19 | 0.140 |
Why?
| Models, Genetic | 1 | 2006 | 209 | 0.140 |
Why?
| Breast Neoplasms | 6 | 1995 | 1248 | 0.140 |
Why?
| Osteogenesis | 2 | 2006 | 377 | 0.140 |
Why?
| Models, Statistical | 1 | 2007 | 259 | 0.130 |
Why?
| Young Adult | 4 | 2019 | 4308 | 0.130 |
Why?
| Mycobacterium tuberculosis | 1 | 2007 | 212 | 0.130 |
Why?
| Metaphase | 3 | 2016 | 55 | 0.130 |
Why?
| Dimethyl Sulfoxide | 2 | 2010 | 13 | 0.130 |
Why?
| Antineoplastic Agents | 5 | 2012 | 1300 | 0.130 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 1995 | 74 | 0.130 |
Why?
| Macrophages | 1 | 2018 | 405 | 0.130 |
Why?
| Cytokines | 2 | 2006 | 676 | 0.130 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 1995 | 116 | 0.130 |
Why?
| Gene Expression Profiling | 2 | 2007 | 1138 | 0.130 |
Why?
| Time Factors | 2 | 2010 | 3212 | 0.130 |
Why?
| Immunoglobulin G | 3 | 2003 | 226 | 0.130 |
Why?
| Risk | 2 | 2017 | 343 | 0.130 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 314 | 0.130 |
Why?
| Acute Disease | 4 | 2013 | 403 | 0.120 |
Why?
| Postoperative Complications | 2 | 2001 | 1033 | 0.120 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 1995 | 180 | 0.120 |
Why?
| Models, Biological | 2 | 2007 | 823 | 0.120 |
Why?
| Etoposide | 5 | 2006 | 85 | 0.120 |
Why?
| Pregnancy | 2 | 2023 | 2620 | 0.120 |
Why?
| Blood Banks | 1 | 2023 | 20 | 0.120 |
Why?
| Sweet Syndrome | 1 | 2003 | 14 | 0.110 |
Why?
| Bone Diseases | 1 | 2004 | 109 | 0.110 |
Why?
| Cyclosporine | 1 | 2003 | 66 | 0.110 |
Why?
| Neoplasms | 4 | 2007 | 1315 | 0.110 |
Why?
| Osteoblasts | 1 | 2006 | 514 | 0.110 |
Why?
| Tacrolimus | 1 | 2003 | 52 | 0.110 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 4 | 0.110 |
Why?
| ABO Blood-Group System | 1 | 2002 | 14 | 0.110 |
Why?
| Hemorrhage | 2 | 2017 | 208 | 0.110 |
Why?
| Prospective Studies | 6 | 2016 | 2604 | 0.110 |
Why?
| Universities | 1 | 2023 | 164 | 0.110 |
Why?
| Coculture Techniques | 3 | 2018 | 160 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2007 | 514 | 0.100 |
Why?
| T-Lymphocytes | 2 | 1998 | 373 | 0.100 |
Why?
| Genetic Therapy | 3 | 1995 | 121 | 0.100 |
Why?
| Cryoprotective Agents | 2 | 1998 | 5 | 0.100 |
Why?
| Ovarian Neoplasms | 1 | 1995 | 472 | 0.100 |
Why?
| Lymphoma, Mantle-Cell | 2 | 2001 | 22 | 0.100 |
Why?
| Hodgkin Disease | 2 | 2002 | 51 | 0.100 |
Why?
| Salvage Therapy | 4 | 2006 | 145 | 0.100 |
Why?
| Platelet Transfusion | 2 | 2010 | 32 | 0.100 |
Why?
| Lymphocyte Depletion | 3 | 1996 | 12 | 0.100 |
Why?
| Osteoclasts | 1 | 2004 | 469 | 0.100 |
Why?
| Tissue Preservation | 2 | 1998 | 9 | 0.090 |
Why?
| Hemagglutination | 1 | 2010 | 3 | 0.090 |
Why?
| Erythrocyte Aggregation | 1 | 2010 | 4 | 0.090 |
Why?
| Cyclosporins | 2 | 1991 | 10 | 0.090 |
Why?
| Tissue Donors | 3 | 2003 | 110 | 0.090 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2012 | 75 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 72 | 0.090 |
Why?
| Erythrocytes | 1 | 2010 | 98 | 0.090 |
Why?
| Thrombosis | 1 | 2003 | 243 | 0.090 |
Why?
| Heart Failure | 1 | 2006 | 541 | 0.090 |
Why?
| Vaccines, DNA | 1 | 1999 | 22 | 0.090 |
Why?
| Erythroid Precursor Cells | 1 | 2019 | 18 | 0.090 |
Why?
| Logistic Models | 3 | 2017 | 990 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2017 | 1304 | 0.080 |
Why?
| Birth Weight | 1 | 2019 | 126 | 0.080 |
Why?
| Graft vs Host Reaction | 1 | 1998 | 2 | 0.080 |
Why?
| Hematocrit | 1 | 2018 | 51 | 0.080 |
Why?
| Antigens, Neoplasm | 2 | 2005 | 170 | 0.080 |
Why?
| Medical Waste | 1 | 2017 | 2 | 0.080 |
Why?
| Survival Analysis | 6 | 2006 | 735 | 0.080 |
Why?
| Cell Aggregation | 1 | 2017 | 6 | 0.080 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2008 | 74 | 0.080 |
Why?
| Neutrophils | 2 | 2006 | 154 | 0.080 |
Why?
| Program Evaluation | 1 | 2019 | 374 | 0.080 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 30 | 0.080 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 52 | 0.070 |
Why?
| Arkansas | 2 | 2017 | 2094 | 0.070 |
Why?
| Neoplasm Proteins | 2 | 2016 | 359 | 0.070 |
Why?
| Lymphocyte Activation | 2 | 1995 | 197 | 0.070 |
Why?
| Fibrosis | 1 | 2017 | 208 | 0.070 |
Why?
| Infant, Newborn | 2 | 2019 | 2907 | 0.070 |
Why?
| Reticulocyte Count | 1 | 2006 | 6 | 0.070 |
Why?
| Tumor Escape | 1 | 2006 | 21 | 0.070 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 106 | 0.070 |
Why?
| Antibodies, Monoclonal | 2 | 2002 | 562 | 0.070 |
Why?
| Adolescent | 5 | 2015 | 6885 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1476 | 0.070 |
Why?
| Glucosylceramidase | 1 | 1995 | 11 | 0.070 |
Why?
| Curriculum | 1 | 2019 | 429 | 0.070 |
Why?
| Membrane Glycoproteins | 3 | 2004 | 269 | 0.070 |
Why?
| Prostatic Neoplasms | 1 | 1999 | 415 | 0.070 |
Why?
| Cytogenetic Analysis | 2 | 2007 | 90 | 0.070 |
Why?
| Hemoglobin J | 1 | 2015 | 3 | 0.070 |
Why?
| Hemoglobin C | 1 | 2015 | 4 | 0.070 |
Why?
| Hemoglobin, Sickle | 1 | 2015 | 7 | 0.070 |
Why?
| Neutropenia | 1 | 2006 | 120 | 0.070 |
Why?
| Hematologic Neoplasms | 1 | 1996 | 99 | 0.060 |
Why?
| Mice | 5 | 2018 | 6413 | 0.060 |
Why?
| Blood Donors | 1 | 2015 | 35 | 0.060 |
Why?
| Clinical Protocols | 2 | 2012 | 122 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1136 | 0.060 |
Why?
| Aged, 80 and over | 3 | 2013 | 3429 | 0.060 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2007 | 434 | 0.060 |
Why?
| Cell Line | 2 | 2008 | 1153 | 0.060 |
Why?
| Autoantibodies | 1 | 2014 | 132 | 0.060 |
Why?
| Specimen Handling | 1 | 1994 | 62 | 0.060 |
Why?
| Feasibility Studies | 2 | 2011 | 398 | 0.060 |
Why?
| Base Sequence | 3 | 1995 | 719 | 0.060 |
Why?
| Age Factors | 3 | 2005 | 1195 | 0.060 |
Why?
| Prednisone | 2 | 2000 | 111 | 0.060 |
Why?
| Multivariate Analysis | 3 | 2007 | 643 | 0.060 |
Why?
| Whole-Body Irradiation | 4 | 1998 | 160 | 0.060 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 35 | 0.060 |
Why?
| Blotting, Western | 1 | 2015 | 683 | 0.060 |
Why?
| Interferon-gamma | 2 | 2010 | 195 | 0.060 |
Why?
| Molecular Sequence Data | 3 | 1995 | 980 | 0.060 |
Why?
| Animals | 7 | 2018 | 14385 | 0.060 |
Why?
| Pulmonary Fibrosis | 2 | 1991 | 20 | 0.060 |
Why?
| Viral Load | 1 | 2013 | 85 | 0.050 |
Why?
| Quality Assurance, Health Care | 1 | 1994 | 164 | 0.050 |
Why?
| Transplantation Chimera | 3 | 2003 | 15 | 0.050 |
Why?
| Pharmacokinetics | 1 | 1992 | 18 | 0.050 |
Why?
| Immunization, Passive | 1 | 1992 | 35 | 0.050 |
Why?
| Bone Marrow Purging | 1 | 1992 | 2 | 0.050 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 31 | 0.050 |
Why?
| Haplotypes | 2 | 2008 | 105 | 0.050 |
Why?
| Benzylamines | 1 | 2012 | 18 | 0.050 |
Why?
| Immunoglobulins | 1 | 1992 | 89 | 0.050 |
Why?
| Infection Control | 1 | 1992 | 57 | 0.050 |
Why?
| Heterocyclic Compounds | 1 | 2012 | 30 | 0.050 |
Why?
| Cohort Studies | 3 | 2006 | 1543 | 0.050 |
Why?
| Kanamycin Kinase | 2 | 1995 | 2 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2015 | 1089 | 0.050 |
Why?
| Urine | 1 | 1991 | 35 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2008 | 569 | 0.050 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2002 | 63 | 0.050 |
Why?
| Microscopy, Electron | 1 | 2001 | 97 | 0.050 |
Why?
| Foscarnet | 1 | 2001 | 3 | 0.050 |
Why?
| DNA Primers | 2 | 1995 | 225 | 0.050 |
Why?
| Immune Tolerance | 1 | 2011 | 104 | 0.050 |
Why?
| Ganciclovir | 1 | 2001 | 35 | 0.050 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 8 | 0.050 |
Why?
| Tumor Cells, Cultured | 2 | 1996 | 477 | 0.050 |
Why?
| Cytomegalovirus | 1 | 2001 | 30 | 0.050 |
Why?
| Child | 5 | 2015 | 7337 | 0.050 |
Why?
| Quality Control | 3 | 2005 | 101 | 0.050 |
Why?
| Chimera | 1 | 1990 | 13 | 0.050 |
Why?
| Isotonic Solutions | 1 | 2010 | 21 | 0.050 |
Why?
| P-Selectin | 1 | 2010 | 33 | 0.050 |
Why?
| Virus Activation | 1 | 2001 | 30 | 0.050 |
Why?
| Antigens, Viral | 1 | 2001 | 58 | 0.050 |
Why?
| Fatal Outcome | 1 | 2001 | 225 | 0.050 |
Why?
| Anemia, Aplastic | 1 | 1990 | 12 | 0.050 |
Why?
| Transfection | 3 | 1999 | 399 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2001 | 168 | 0.050 |
Why?
| Platelet Aggregation | 1 | 2010 | 82 | 0.050 |
Why?
| Platelet Activation | 1 | 2010 | 50 | 0.050 |
Why?
| Sodium Chloride | 1 | 2010 | 67 | 0.050 |
Why?
| Angiogenesis Inhibitors | 2 | 2007 | 203 | 0.050 |
Why?
| Algorithms | 2 | 2005 | 697 | 0.050 |
Why?
| Hypersensitivity | 1 | 2010 | 82 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1048 | 0.040 |
Why?
| Survival Rate | 2 | 2006 | 951 | 0.040 |
Why?
| Polyomavirus | 1 | 1989 | 5 | 0.040 |
Why?
| Peripheral Nervous System Diseases | 1 | 1990 | 63 | 0.040 |
Why?
| Antiviral Agents | 1 | 2001 | 188 | 0.040 |
Why?
| Cystitis | 1 | 1989 | 18 | 0.040 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2007 | 191 | 0.040 |
Why?
| Polymerase Chain Reaction | 2 | 1995 | 531 | 0.040 |
Why?
| Ultraviolet Rays | 1 | 1989 | 56 | 0.040 |
Why?
| Glucocorticoids | 1 | 2000 | 234 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 83 | 0.040 |
Why?
| Arginase | 1 | 2018 | 39 | 0.040 |
Why?
| Ligands | 1 | 2008 | 230 | 0.040 |
Why?
| Hemoglobins | 1 | 2008 | 126 | 0.040 |
Why?
| Carrier Proteins | 2 | 2004 | 359 | 0.040 |
Why?
| Polyethylene Glycols | 1 | 2008 | 106 | 0.040 |
Why?
| Pilot Projects | 1 | 2000 | 808 | 0.040 |
Why?
| DNA | 1 | 1991 | 581 | 0.040 |
Why?
| Cisplatin | 3 | 2006 | 352 | 0.040 |
Why?
| Age Distribution | 1 | 2007 | 198 | 0.040 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.040 |
Why?
| Theophylline | 1 | 2007 | 24 | 0.040 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.040 |
Why?
| Chromosome Deletion | 1 | 2007 | 150 | 0.040 |
Why?
| Chromosome Mapping | 1 | 2006 | 175 | 0.040 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2007 | 278 | 0.040 |
Why?
| Benzopyrenes | 1 | 1975 | 6 | 0.030 |
Why?
| 3T3 Cells | 1 | 1995 | 52 | 0.030 |
Why?
| Epithelium | 1 | 1975 | 68 | 0.030 |
Why?
| Cytotoxicity, Immunologic | 1 | 1995 | 62 | 0.030 |
Why?
| Interleukin-2 | 1 | 1995 | 75 | 0.030 |
Why?
| Cell Communication | 1 | 2006 | 72 | 0.030 |
Why?
| Interleukin-10 | 1 | 2006 | 107 | 0.030 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 115 | 0.030 |
Why?
| Apoptosis | 1 | 2001 | 1300 | 0.030 |
Why?
| Life Tables | 2 | 2002 | 8 | 0.030 |
Why?
| Stroke Volume | 1 | 2006 | 150 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2006 | 98 | 0.030 |
Why?
| Liver | 1 | 2001 | 1225 | 0.030 |
Why?
| Ficoll | 2 | 1996 | 2 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2006 | 127 | 0.030 |
Why?
| Databases, Factual | 1 | 2007 | 684 | 0.030 |
Why?
| Bromodeoxyuridine | 1 | 2004 | 20 | 0.030 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 32 | 0.030 |
Why?
| Annexin A5 | 1 | 2004 | 14 | 0.030 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 52 | 0.030 |
Why?
| Phagocytosis | 1 | 2004 | 51 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2006 | 656 | 0.030 |
Why?
| Epithelial Cells | 1 | 1975 | 255 | 0.030 |
Why?
| Immunotherapy | 2 | 2002 | 263 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 26 | 0.030 |
Why?
| Syndecans | 1 | 2003 | 43 | 0.030 |
Why?
| Paraproteins | 1 | 2003 | 13 | 0.030 |
Why?
| Ifosfamide | 2 | 1993 | 8 | 0.030 |
Why?
| Syndecan-1 | 1 | 2003 | 82 | 0.030 |
Why?
| Plasmapheresis | 1 | 2003 | 14 | 0.030 |
Why?
| Cell Division | 1 | 2004 | 330 | 0.030 |
Why?
| Chronic Disease | 1 | 2006 | 612 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 165 | 0.030 |
Why?
| Proteoglycans | 1 | 2003 | 96 | 0.030 |
Why?
| RANK Ligand | 1 | 2004 | 183 | 0.030 |
Why?
| Remission Induction | 2 | 2003 | 221 | 0.030 |
Why?
| Interleukin-6 | 1 | 2004 | 315 | 0.030 |
Why?
| Infusions, Intravenous | 2 | 2003 | 231 | 0.030 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 9 | 0.030 |
Why?
| Blood Transfusion, Autologous | 2 | 1992 | 5 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2003 | 401 | 0.030 |
Why?
| NF-kappa B | 1 | 2004 | 335 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2006 | 1084 | 0.030 |
Why?
| Graft Rejection | 1 | 2002 | 161 | 0.020 |
Why?
| Cell Differentiation | 1 | 2004 | 720 | 0.020 |
Why?
| Colony-Forming Units Assay | 2 | 1992 | 31 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 2 | 2003 | 309 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 15 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 18 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 48 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 80 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 61 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2006 | 1639 | 0.020 |
Why?
| Biotechnology | 1 | 1999 | 14 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1604 | 0.020 |
Why?
| Immunologic Surveillance | 1 | 1999 | 14 | 0.020 |
Why?
| Child, Preschool | 3 | 1994 | 4146 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2010 | 176 | 0.020 |
Why?
| Drug Resistance | 1 | 1998 | 74 | 0.020 |
Why?
| Steroids | 1 | 1998 | 53 | 0.020 |
Why?
| Chromatography, Gas | 1 | 1998 | 16 | 0.020 |
Why?
| Vaccination | 1 | 2010 | 293 | 0.020 |
Why?
| Secondary Prevention | 1 | 1998 | 89 | 0.020 |
Why?
| Neomycin | 1 | 1997 | 4 | 0.020 |
Why?
| Drug Resistance, Microbial | 1 | 1997 | 51 | 0.020 |
Why?
| Leukemia, Erythroblastic, Acute | 1 | 1996 | 6 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 1996 | 26 | 0.020 |
Why?
| Solutions | 1 | 1996 | 29 | 0.020 |
Why?
| Stromal Cells | 1 | 1997 | 79 | 0.020 |
Why?
| Indicators and Reagents | 1 | 1996 | 42 | 0.020 |
Why?
| Rats | 2 | 1998 | 3415 | 0.020 |
Why?
| Clone Cells | 1 | 2006 | 89 | 0.020 |
Why?
| Deoxycytidine | 1 | 2006 | 28 | 0.020 |
Why?
| Temperature | 1 | 1996 | 177 | 0.020 |
Why?
| Genes | 1 | 1995 | 38 | 0.020 |
Why?
| Transduction, Genetic | 1 | 1995 | 50 | 0.020 |
Why?
| In Situ Hybridization | 1 | 1995 | 82 | 0.020 |
Why?
| Chromatography, Affinity | 1 | 1995 | 50 | 0.020 |
Why?
| Fluorouracil | 1 | 1995 | 61 | 0.020 |
Why?
| Genes, Reporter | 1 | 1995 | 98 | 0.020 |
Why?
| Genetic Markers | 1 | 1995 | 117 | 0.020 |
Why?
| Recovery of Function | 1 | 2006 | 222 | 0.020 |
Why?
| Lymphocyte Subsets | 1 | 1994 | 13 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 1995 | 368 | 0.020 |
Why?
| Propidium | 1 | 1994 | 3 | 0.020 |
Why?
| Kinetics | 1 | 2006 | 692 | 0.020 |
Why?
| Macaca mulatta | 1 | 1994 | 106 | 0.020 |
Why?
| T-Lymphocyte Subsets | 1 | 1994 | 41 | 0.010 |
Why?
| Immunophenotyping | 1 | 1994 | 117 | 0.010 |
Why?
| Oligodeoxyribonucleotides | 1 | 1993 | 30 | 0.010 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 167 | 0.010 |
Why?
| Cell Nucleus | 1 | 1994 | 203 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 77 | 0.010 |
Why?
| Probability | 1 | 2003 | 176 | 0.010 |
Why?
| Academic Medical Centers | 1 | 1994 | 141 | 0.010 |
Why?
| Cell Death | 1 | 1994 | 223 | 0.010 |
Why?
| Data Interpretation, Statistical | 1 | 1994 | 177 | 0.010 |
Why?
| Carboplatin | 1 | 1992 | 62 | 0.010 |
Why?
| Multiple Organ Failure | 1 | 2002 | 56 | 0.010 |
Why?
| Mutation | 1 | 1999 | 1501 | 0.010 |
Why?
| Neoplasm Metastasis | 1 | 1993 | 252 | 0.010 |
Why?
| Injections, Intravenous | 1 | 1992 | 148 | 0.010 |
Why?
| Statistics as Topic | 1 | 1992 | 103 | 0.010 |
Why?
| Leukopenia | 1 | 1992 | 11 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 459 | 0.010 |
Why?
| Blood Cell Count | 1 | 1992 | 43 | 0.010 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 55 | 0.010 |
Why?
| Doxorubicin | 1 | 2003 | 259 | 0.010 |
Why?
| Linear Models | 1 | 1992 | 309 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 1992 | 431 | 0.010 |
Why?
| HLA Antigens | 1 | 1990 | 55 | 0.010 |
Why?
| Pedigree | 1 | 1990 | 146 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2003 | 806 | 0.010 |
Why?
| Muscle Cramp | 1 | 1990 | 5 | 0.010 |
Why?
| Bacterial Infections | 1 | 1991 | 105 | 0.010 |
Why?
| Mycoses | 1 | 1991 | 162 | 0.010 |
Why?
| Postoperative Period | 1 | 1990 | 189 | 0.010 |
Why?
| Software | 1 | 1992 | 296 | 0.010 |
Why?
| Busulfan | 1 | 1989 | 18 | 0.010 |
Why?
| Disease Progression | 1 | 2003 | 913 | 0.010 |
Why?
| Sepsis | 1 | 2002 | 251 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 1989 | 43 | 0.010 |
Why?
| Hematopoiesis | 1 | 1989 | 80 | 0.010 |
Why?
| Dose-Response Relationship, Radiation | 1 | 1989 | 204 | 0.010 |
Why?
| Glycols | 1 | 1975 | 3 | 0.010 |
Why?
| Quinones | 1 | 1975 | 11 | 0.010 |
Why?
| Hydrocortisone | 1 | 1975 | 124 | 0.010 |
Why?
| Microsomes, Liver | 1 | 1975 | 214 | 0.010 |
Why?
| Phenols | 1 | 1975 | 120 | 0.010 |
Why?
| Fibroblasts | 1 | 1975 | 386 | 0.010 |
Why?
| Infant | 1 | 1990 | 3817 | 0.010 |
Why?
| Cells, Cultured | 1 | 1975 | 1737 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|